Sphingosine Kinase Shows Promise as New Target for Viral Lymphomas
Friday, 31 January 2014
A new paper from researchers at Louisiana State University Health Sciences Center, is the first to report that sphingolipids, specialized fat molecules, are vital to the survival of aggressive lymphomas caused by viruses. The paper, published in the January issue of Molecular Cancer Therapeutics, also identifies a small molecule inhibitor of the sphingosine kinase (SPHK)
- Published in Emerging Targets
No Comments
Battling Lysosomal Storage Diseases with ERT and SRT
Friday, 01 November 2013
Lysosomal storage diseases (LSDs) are caused by deficiencies in lysosomal enzymes needed to recycle various cell components, resulting in toxic accumulation of metabolites (Table 1). They are complex diseases that damage multiple organs and cause a diverse array of debilitating and painful symptoms; most cause neuromuscular problems and many inflict neurological damage such as mental
- Published in Emerging Targets
Greatwall: Cancer’s Great Defender?
Friday, 25 October 2013
Inhibiting Greatwall may provoke mitotic collapse and suppress tumor growth. Emerging research from the Spanish National Cancer Research Centre (CNIO) sheds new light on the relationship between the protein kinase Greatwall and successful cell division and suggests the protein as a novel oncogenic target. Greatwall was originally identified in Drosophila as a protein required for
- Published in Emerging Targets
Helicases as Drug Discovery Targets
Wednesday, 09 October 2013
Helicases – ATP-powered nucleic acid unwinding enzymes – are an interesting therapeutic target class, being pursued for both infectious diseases and cancer. The rationale for inhibiting helicases in viruses, bacteria, and cancer cells is similar: they are required for replication and/or repair of their respective genomes. A recent review from David Frick’s group at the
- Published in Emerging Targets
BellBrook Labs Launches HTS Assay Platform for Targeting GPCR Regulatory Proteins
Tuesday, 09 October 2012
BellBrook Labs launched a comprehensive HTS assay reagent platform for “Regulators of G-protein Signaling” (RGS) protein, a family of proteins that shows promise as drug targets because of their emerging role in regulating G Protein-Coupled Receptors (GPCRs). The proprietary RGScreen technology, which combines kinetically enhanced recombinant proteins with BellBrook’s Transcreener GDP Assay, opens up new
- Published in Emerging Targets
ADP Detection: It’s not all about kinases
Wednesday, 25 July 2012
The publication of a successful RecA screen by Scott Singleton’s group at the University of North Carolina, Chapel Hill brought the total number of peer-reviewed papers referencing the Transcreener ADP Assay, BellBrook’s fluorescent ADP detection assay, to an even dozen. Ten of these are focused on specific drug targets, half of those on enzymes other than
- Published in Emerging Targets
